We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Employed for Extrapulmonary TB Specimens

By LabMedica International staff writers
Posted on 05 Apr 2012
The laboratory diagnosis of tuberculosis (TB) on extrapulmonary specimens is particularly challenging, as invasive procedures are often required in order to obtain samples for culture.

A number of commercial nucleic acid amplification tests able to detect and identify Mycobacterium tuberculosis (MTB) complex directly from respiratory secretions have been developed, but their use on extrapulmonary samples still calls for validation.

Scientists at the United Hospitals (Ancona, Italy) performed a retrospective analysis aiming to evaluate the diagnostic accuracy of a Complex Direct Detection Assay (DTB) on 918 nonrespiratory specimens collected from 863 patients investigated for TB based on different levels of clinical suspicion, between January 2006 and December 2009. The specimens included 84 gastric aspirates, 145 urine, 136 sterile body fluids, 83 cerebrospinal (CSF) fluids, 237 fine-needle aspirates, 175 pus, 56 biopsies, and 2 stool specimens.

The results were compared with those of acid-fast staining and culture, solid plus liquid media, setting the combination of culture and clinical diagnosis as the gold standard. Ninety-two specimens yielded culture positive for MTB and 24 who were smear and culture negative were from patients with TB clinical diagnosis. Of these patients, 96 were positive with the BDProbeTec ET Mycobacterium tuberculosis Complex Direct Detection Assay (DTB, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) including all of those from culture-negative TB cases. From 26 specimens, nontuberculous mycobacteria were grown and two of these specimens were positive by the DTB assay.

The authors concluded that the overall sensitivity, specificity, and positive and negative predictive values of the DTB assay for extrapulmonary TB were high. A reduced sensitivity of 73.5% was observed among smear-negative specimens when compared with 91.7% for smear-positives specimens. Although amplification assays cannot replace culture techniques, DTB proved to be rapid and specific for the detection of MTB in extrapulmonary samples. The study was published in the March 2012 issue of the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:
United Hospitals
Becton, Dickinson and Company


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.